Foghorn Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

FHTX$1.90-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’

Condensed Consolidated Statements of Stockholders’ Deficit

(In thousands, except share amounts)

Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Gain (Loss) · AccumulatedDeficit · TotalStockholders’Deficit
Shares · Amount
Balances at December 31, 2025	56,657,329	$6	$523,937	$24	$(632,467)	$(108,500)
Issuance of common stock from direct offering, net of offering costs	2,030,314	—	10,213	—	—	10,213
Issuance of pre-funded warrants from direct offering, net of offering costs	—	—	27,271	—	—	27,271
Issuance of series 1 warrants from direct offering, net of offering costs	—	—	2,942	—	—	2,942
Issuance of series 2 warrants from direct offering, net of offering costs	—	—	9,226	—	—	9,226
Issuance of common stock upon exercise of stock options and employee stock purchase plan	22,847	—	89	—	—	89
Stock-based compensation expense	—	—	2,383	—	—	2,383
Unrealized losses on marketable securities	—	—	—	(157)	—	(157)
Net loss	—	—	—	—	(19,875)	(19,875)
Balances at March 31, 2026	58,710,490	6	576,061	(133)	(652,342)	(76,408)
Issuance of common stock upon exercise of stock options and employee stock purchase plan	3,782	—	9	—	—	9
Stock-based compensation expense	—	—	2,550	—	—	2,550
Unrealized losses on marketable securities	—	—	—	(1)	—	(1)
Net loss	—	—	—	—	(7,191)	(7,191)
Balances at June 30, 2026	58,714,272	6	578,620	(134)	(659,533)	(81,041)
Issuance of common stock upon exercise of stock options and employee stock purchase plan	134,335	—	480	—	—	480
Issuance of common stock upon exercise of pre-funded warrants	113,500	—	—	—	—	—
Issuance of common stock under the ATM Facility, net of issuance costs	1,000,543	—	5,796	—	—	5,796
Stock-based compensation expense	—	—	2,520	—	—	2,520
Unrealized gains on marketable securities	—	—	—	11	—	11
Net income	—	—	—	—	58,150	58,150
Balances at September 30, 2026	59,962,650	$6	$587,416	$(123)	$(601,383)	$(14,084)

Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Gain (Loss) · AccumulatedDeficit · TotalStockholders’Deficit
Shares · Amount
Balances at December 31, 2024	55,594,131	$6	$512,515	$135	$(558,184)	$(45,528)
Issuance of common stock upon exercise of stock options and employee stock purchase plan	127,209	—	139	—	—	139
Stock-based compensation expense	—	—	2,692	—	—	2,692
Unrealized losses on marketable securities	—	—	—	(121)	—	(121)
Net loss	—	—	—	—	(18,834)	(18,834)
Balances at March 31, 2025	55,721,340	6	515,346	14	(577,018)	(61,652)
Issuance of common stock upon exercise of stock options and employee stock purchase plan	81,855	—	254	—	—	254
Stock-based compensation expense	—	—	2,733	—	—	2,733
Unrealized losses on marketable securities	—	—	—	(58)	—	(58)
Net loss	—	—	—	—	(17,936)	(17,936)
Balances at June 30, 2025	55,803,195	6	518,333	(44)	(594,954)	(76,659)
Issuance of common stock upon exercise of stock options and employee stock purchase plan	13,733	—	49	—	—	49
Issuance of common stock upon exercise of pre-funded warrants	725,949	—	—	—	—	—
Stock-based compensation expense	—	—	2,733	—	—	2,733
Unrealized gains on marketable securities	—	—	—	68	—	68
Net loss	—	—	—	—	(15,849)	(15,849)
Balances at September 30, 2025	56,542,877	$6	$521,115	$24	$(610,803)	$(89,658)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.